Abdullah Mohamed A, Amer Aliaa, Nawaz Zafar, Abdullah Ali S, Al-Sabbagh Ahmad, Kohla Samah, Nashwan Abdulqadir J, Yassin Mohamed A
Department of Medical Oncology, Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.
Acta Biomed. 2018 Apr 3;89(3-S):28-32. doi: 10.23750/abm.v89i3-S.7217.
Chronic Myeloid Leukemia (CML) is myeloproliferative neoplasm characterized by Philadelphia chromosome which is a balanced translocation between chromosome 9 and 22 in 90% of cases. However, variant cytogenetic still happens in 5-10 % of cases, the importance of which is controversial as well as its response to therapy, prognosis and progression to acute leukemias. Here we report a male patient with CML and variant cytogenetic who responded to low dose of Dasatinib (50 mg daily).
慢性粒细胞白血病（CML）是一种骨髓增殖性肿瘤，其特征是费城染色体，在90%的病例中，该染色体是9号和22号染色体之间的平衡易位。然而，5%-10%的病例仍会出现细胞遗传学变异，其重要性以及对治疗的反应、预后和向急性白血病的进展存在争议。在此，我们报告一名患有CML和细胞遗传学变异的男性患者，其对低剂量达沙替尼（每日50毫克）有反应。
